Biovica International AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
04-13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
04-12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Sales 2024 * | 10M 933K 73.49M | Sales 2025 * | 116M 10.83M 852M | Capitalization | 134M 12.55M 988M |
---|---|---|---|---|---|
Net income 2024 * | -115M -10.73M -845M | Net income 2025 * | -60M -5.6M -441M | EV / Sales 2024 * | 6.1 x |
Net cash position 2024 * | 73.52M 6.86M 540M | Net cash position 2025 * | 45.95M 4.29M 338M | EV / Sales 2025 * | 0.76 x |
P/E ratio 2024 * |
-0.22
x | P/E ratio 2025 * |
-0.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 31/12/09 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 31/12/22 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19/03/19 | |
Annika Berg
BRD | Director/Board Member | 61 | 31/12/19 |
Maria Holmlund
BRD | Director/Board Member | 68 | 31/12/15 |
1st Jan change | Capi. | |
---|---|---|
-31.90% | 9.3B | |
-6.25% | 3.1B | |
+25.95% | 2.87B | |
-13.96% | 2.17B | |
-16.83% | 1.75B | |
+72.82% | 1.5B | |
+29.17% | 807M | |
-2.62% | 759M | |
-26.33% | 532M |